Drugs / cleminorexton
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07598708 | May 2026 → Sep 2027 expected | narcolepsy 1, narcolepsy without cataplexy | Centessa Pharmaceuticals (UK) Limited | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cleminorexton | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07598708 ↗ |
| Route | Oral | “Oral cleminorexton capsule” NCT07598708 ↗ |